2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 694

Serum Wisteria Floribunda Agglutinin-Positive Mac-2-Binding Protein Can Reflect Systemic Lupus Erythematosus Activity
Abstract Number: 538

Severe Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
Abstract Number: 2773

Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88
Abstract Number: 2359

Severity of Ischemic and Hemorrhagic Stroke in Patients with Rheumatoid Arthritis Compared with the General Population
Abstract Number: 1006

Sex Differences in Depressive Symptom Subtypes in Knee Osteoarthritis
Abstract Number: 1109

Sex Differences in Gout Patients: Epidemiology, Flares and Hospitalization Data in a Population Based Cohort
Abstract Number: 1816

Sex Differences in Orthopedic Surgery Among Patients with Rheumatoid Arthritis
Abstract Number: 1501

Sexual Dysfunction and Vaginal Dryness Are Common in Female Patients with Early, Active Primary Sjogren’s Syndrome
Abstract Number: 1637

Sexual Function in Married Indian Women with Systemic Lupus Erythematosus
Abstract Number: 2563

SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
Abstract Number: 1526

Shift Analysis of Spinal Radiographic Progression after 2 Years of Secukinumab in Ankylosing Spondylitis – Detailed Results from a Phase 3 Trial
Abstract Number: 2857

Short and Long-Term Follow-up of Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis
Abstract Number: 780

Short and Long-Term Follow-up with Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 49 Patients of Clinical Practice
Abstract Number: 635

Short-Term Efficacy and Safety of New Biological Agents Targeting the IL-6, IL-12/23 and IL-17 Pathways for Active Psoriatic Arthritis: A Network Meta-Analysis of Randomised Controlled Trials
Abstract Number: 366

Short-Term Outcomes in Patients with Systemic-Onset Juvenile Idiopathic Arthritis Treated with Either Tocilizumab or Anakinra in a Real-World Setting in the United Kingdom

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].